Why CRISPR Has Only Helped 40 People (And How That Might Change)

The Shift

Here's a number that should surprise you: after years of breathless headlines about CRISPR revolutionizing medicine, exactly one gene-editing drug has been approved, and it's been used in about 40 patients.

The problem isn't that CRISPR doesn't work—it does. The problem is money. Rare genetic diseases, by definition, affect small numbers of people. Running a full clinical trial costs hundreds of millions of dollars. When only a few thousand patients exist worldwide for a given condition, the math simply doesn't work. No pharmaceutical company will spend $300 million developing a treatment they can only sell to 500 people.

This creates a cruel paradox: CRISPR is theoretically perfect for rare genetic diseases (fix the broken gene, fix the disease), but economically impossible to deploy for most of them.

The Solution

Aurora Therapeutics thinks the answer isn't better science—it's a regulatory workaround.

Think of it like car safety testing. Imagine if every single car model required its own 5-year crash test program, even if it used the same frame, engine, and safety systems as an already-approved vehicle. That's essentially how drug approval works today. Aurora wants to convince the FDA to accept a different model: prove the "platform" works once, then approve variations with minimal extra testing.

The FDA has been quietly moving in this direction with something called the "plausible mechanism" framework. If a company can demonstrate that Treatment A fixes Gene Mutation A through a well-understood biological process, and Gene Mutation B is similar enough, regulators might accept that Treatment B will likely work too—without requiring another full clinical trial.

Aurora's co-founders have serious credibility here: Jennifer Doudna won the Nobel Prize for co-inventing CRISPR, and Fyodor Urnov is one of the field's most respected scientists. Their CEO, Ed Kaye, previously led companies that successfully navigated tricky FDA pathways for rare diseases.

The Impact

If the FDA accepts Aurora's approach, the business case for rare disease treatment changes dramatically.

Currently, drug companies chase "blockbuster" conditions affecting millions of patients because that's the only way to recoup R&D costs. Under a platform model, a company could develop one core technology, prove it works, then efficiently expand to treat dozens of related conditions—each with only hundreds or thousands of patients.

This isn't charity; it's better economics. Instead of one $500 million bet on one disease, companies could make many smaller bets that collectively serve far more patients.

For the estimated 400 million people worldwide living with rare genetic diseases, this shift could mean the difference between "your condition is too uncommon to treat" and "we have a therapy for that."

Real World Example

Aurora's first target is phenylketonuria, or PKU—a metabolic disorder that prevents the body from processing a common amino acid found in protein. Left untreated, it causes severe intellectual disability. Currently, the 13,500 Americans with PKU manage it through an extremely restrictive diet that many find difficult to maintain.

PKU is caused by mutations in the PAH gene, but there are many different mutations that can cause the disease. Aurora is starting with the three most common ones. Under the traditional model, each mutation would require its own clinical trial—economically impossible. Under the platform model, proving the treatment works for one mutation could pave the way for FDA approval of treatments for related mutations with far less additional testing.

If it works for PKU, Aurora's approach becomes a template. Hundreds of other genetic conditions share the same economic problem: proven science, impossible business case. A regulatory green light here could open the floodgates.